HLB Presents Promising Interim Results of Rivoceranib at ESMO 2024

· HLB's rivoceranib combination therapies show potential for expanded indications.

Rivoceranib research findings poster presentation site at ESMO 2024 (Credit: HLB)

SEOUL, South Korea, September 19, 2024 (IT Times) - HLB, a leading biopharmaceutical company, today announced that its subsidiary Eleva Therapeutics and its partner, Jiangsu Hengrui Pharmaceuticals, presented 11 study results related to rivoceranib at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain.

Rivoceranib, a targeted therapy for advanced cancers, demonstrated positive outcomes in various clinical trials. Eleva presented results from its Phase 1 study evaluating the safety and efficacy of rivoceranib in combination with nivolumab (Opdivo), as well as sub-analyses on anti-drug antibody response and quality of life. The combination therapy showed promising results in metastatic solid tumors and minimal anti-drug antibody response.

Jiangsu Hengrui Pharmaceuticals announced Phase 3 results in breast cancer, further expanding rivoceranib's potential indications. In patients with HER2-positive breast cancer and BRCA1/2 mutations, rivoceranib in combination with fluzoparib demonstrated significant improvements in progression-free survival and objective response rate.

At ESMO 2024, HLB Group CTO Yong-hae Han and Elevar CEO Se-ho Jeong spoke to the media and said that all procedures are progressing smoothly, including preparations for the submission of the supplemental New Drug Application for liver cancer, which is scheduled to be submitted this week. "In addition to the FDA approval process, we are currently in discussions with several companies for European distribution rights or combination clinical trials for expansion beyond liver cancer," Jeong said, adding that the company will continue to expand the value of rivoceranib.

IT Times : https://www.ittimes.com/news/articleView.html?idxno=48694

HLB Presents Promising Interim Results of Rivoceranib at ESMO 2024 - IT타임스